A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein

Takagi, 2006, A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan, Mol Pharm, 3, 631, 10.1021/mp0600182 Ashour, 2016, Hot melt extrusion as an approach to improve solubility, permeability and oral absorption of a psychoactive natural product, piperine, J Pharm Pharmacol, 68, 989, 10.1111/jphp.12579 Hao, 2015, Enhancement of solubility, transport across Madin-Darby Canine Kidney monolayers and oral absorption of Pranlukast through preparation of a Pranlukast-phospholipid complex, J Biomed Nanotechnol, 11, 469, 10.1166/jbn.2015.1914 Kim, 2013, Enhanced solubility and oral absorption of sirolimus using D-alpha-tocopheryl polyethylene glycol succinate micelles, Artif Cells Nanomed Biotechnol, 41, 85, 10.3109/21691401.2012.742100 Qiao, 2011, Pharmaceutical cocrystals: an overview, Int J Pharm, 419, 1, 10.1016/j.ijpharm.2011.07.037 Thakuria, 2013, Pharmaceutical cocrystals and poorly soluble drugs, Int J Pharm, 453, 101, 10.1016/j.ijpharm.2012.10.043 Rahman, 2011, Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide, AAPS PharmSciTech, 12, 693, 10.1208/s12249-011-9603-4 Tomaszewska, 2013, Pharmaceutical characterisation and evaluation of cocrystals: importance of in vitro dissolution conditions and type of coformer, Int J Pharm, 453, 380, 10.1016/j.ijpharm.2013.05.048 Hong, 2015, A novel strategy for pharmaceutical cocrystal generation without knowledge of stoichiometric ratio: myricetin cocrystals and a ternary phase diagram, Pharm Res, 32, 47, 10.1007/s11095-014-1443-y Huang, 2014, Baicalein-nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioavailability, J Pharm Sci, 103, 2330, 10.1002/jps.24048 McNamara, 2006, Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API, Pharm Res, 23, 1888, 10.1007/s11095-006-9032-3 Müller, 2012, Twenty years of drug nanocrystals: Where are we, and where do we go?, Eur J Pharm Biopharm, 80, 1, 10.1016/j.ejpb.2011.09.012 Pi, 2016, Ursolic acid nanocrystals for dissolution rate and bioavailability enhancement: influence of different particle size, Curr Drug Deliv, 13, 1358, 10.2174/1567201813666160307142757 Zuo, 2013, Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals, Int J Pharm, 455, 267, 10.1016/j.ijpharm.2013.07.021 Zhang, 2011, Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal, Int J Pharm, 420, 180, 10.1016/j.ijpharm.2011.08.023 Hao, 2012, Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals, Int J Pharm, 433, 157, 10.1016/j.ijpharm.2012.05.002 Kesisoglou, 2007, Nanosizing-oral formulation development and biopharmaceutical evaluation, Adv Drug Deliv Rev, 59, 631, 10.1016/j.addr.2007.05.003 Junghanns, 2008, Nanocrystal technology, drug delivery and clinical applications, Int J Nanomedicine, 3, 295 De Smet, 2014, Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs, Eur J Pharm Biopharm, 87, 107, 10.1016/j.ejpb.2013.12.016 Karashima, 2016, A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologies, Eur J Pharm Biopharm, 107, 142, 10.1016/j.ejpb.2016.07.006 Liu, 2016, The generation of myricetin-nicotinamide nanococrystals by top down and bottom up technologies, Nanotechnology, 27, 10.1088/0957-4484/27/39/395601 Huang, 2017, Phenazopyridine-phthalimide nano-cocrystal: Release rate and oral bioavailability enhancement, Eur J Pharm Sci, 109, 581, 10.1016/j.ejps.2017.09.020 Miocinovic, 2005, In vivo and in vitro effect of baicalein on human prostate cancer cells, Int J Oncol, 26, 241 Fan, 2013, Anti-inflammatory activity of baicalein in LPS-stimulated RAW264.7 macrophages via estrogen receptor and NF-kappaB-dependent pathways, Inflammation, 36, 1584, 10.1007/s10753-013-9703-2 Huang, 2005, Biological properties of baicalein in cardiovascular system, Curr Drug Targets Cardiovasc Haematol Disord, 5, 177, 10.2174/1568006043586206 Sowa, 2012, A 1:1 cocrystal of baicalein with nicotinamide, Acta Crystallogr C, 68, 262, 10.1107/S0108270112024456 Zeng, 2014, Simultaneous multi-component quantitation of Chinese herbal injection Yin-zhi-huang in rat plasma by using a single-tube extraction procedure for mass spectrometry-based pharmacokinetic measurement, J Chromatogr B Analyt Technol Biomed Life Sci, 967, 245, 10.1016/j.jchromb.2014.07.037 Xie, 2010, Integral pharmacokinetics of multiple lignan components in normal, CCl4-induced hepatic injury and hepatoprotective agents pretreated rats and correlations with hepatic injury biomarkers, J Ethnopharmacol, 131, 290, 10.1016/j.jep.2010.06.038 Karki, 2007, Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding, Mol Pharm, 4, 347, 10.1021/mp0700054 Dhumal, 2010, Cocrystalization and simultaneous agglomeration using hot melt extrusion, Pharm Res, 27, 2725, 10.1007/s11095-010-0273-9 Brough, 2013, Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery, Int J Pharm, 453, 157, 10.1016/j.ijpharm.2013.05.061 Hasa, 2013, Reduction of melting temperature and enthalpy of drug crystals: theoretical aspects, Eur J Pharm Sci, 50, 17, 10.1016/j.ejps.2013.03.018 Kerr, 2017, Structure and physicochemical characterization of a naproxen-picolinamide cocrystal, Acta Crystallogr C Struct Chem, 73, 168, 10.1107/S2053229616011980 Hecq, 2006, Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base, Eur J Pharm Biopharm, 64, 360, 10.1016/j.ejpb.2006.05.008 Gao, 2012, Drug nanocrystals: In vivo performances, J Control Release, 160, 418, 10.1016/j.jconrel.2012.03.013 Shegokar, 2010, Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives, Int J Pharm, 399, 129, 10.1016/j.ijpharm.2010.07.044 Tu, 2013, Effects of particle size on the pharmacokinetics of puerarin nanocrystals and microcrystals after oral administration to rat, Int J Pharm, 458, 135, 10.1016/j.ijpharm.2013.10.001 Akao, 2009, Hepatic contribution to a marked increase in the plasma concentration of baicalin after oral administration of its aglycone, baicalein, in multidrug resistance-associated protein 2-deficient rat, Biol Pharm Bull, 32, 2079, 10.1248/bpb.32.2079 Zhang, 2005, Role of intestinal first-pass metabolism of baicalein in its absorption process, Pharm Res, 22, 1050, 10.1007/s11095-005-5303-7 Kang, 2014, Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin, Arch Pharm Res, 37, 371, 10.1007/s12272-013-0179-2 Wang, 2015, Simultaneous determination of ten active constituents of Yankening Capsule in rat plasma by ultra high performance liquid chromatography with tandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, 978-979, 43, 10.1016/j.jchromb.2014.10.016 Qian, 2017, Pharmacokinetics studies of 12 alkaloids in rat plasma after oral administration of Zuojin and Fan-Zuojin formulas, Molecules, 22, 214, 10.3390/molecules22020214 Alam, 2013, Commercially bioavailable proprietary technologies and their marketed products, Drug Discov Today, 18, 936, 10.1016/j.drudis.2013.05.007